crisnatol mesylate

An anticancer drug that interferes with the DNA in cancer cells.
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

crisnatol

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1999
1999
A phase I and pharmacological study of protracted infusions of crisnatol mesylate in patients with solid malignancies.
This Phase I and pharmacological study was performed to assess the feasibility of administering the polycyclic aromatic… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
1997
1997
Long-term response to crisnatol mesylate in patients with glioma.
A total of 26 patients (6 with anaplastic astrocytoma; 20 with glioblastoma) were treated with crisnatol mesylate. All patients… (More)
Is this relevant?
1992
1992
A phase II study of crisnatol mesylate in patients with ovarian carcinoma
Fourteen patients with advanced ovarian cancer received a 72 hour infusion of a new DNA intercalator, crisnatol mesylate… (More)
  • table 2
Is this relevant?
1992
1992
Microbial Production of a Crisnatol Metabolite
Microbial metabolism studies of crisnatol (1), a new DNA interca-lator, has resulted in the isolation and characterization of a… (More)
Is this relevant?
1991
1991
Crisnatol mesylate: Phase I dose escalation by extending infusion duration
Crisnatol mesylate is a rationally designed cytotoxic arylmethylamino-propanediol with broad spectrum cytotoxic activity. A phase… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
Is this relevant?
1990
1990
Evaluation of arylmethylaminopropanediols by a novel in vitro pharmacodynamic assay: correlation with antitumor activity in vivo.
The pharmacodynamics of a new series of antitumor DNA intercalators, known as arylmethylaminopropanediols (AMAPs), has been… (More)
Is this relevant?